Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

NCT02956421 is registered in ClinicalTrials.gov with Yisheng Biopharma (Singapore) Pte. Ltd. as lead sponsor.

NCT NCT02956421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02956421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen
Lead sponsor
Yisheng Biopharma (Singapore) Pte. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2016
Completion date
October 31, 2016
Enrollment
126 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rabies